| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Mrz―23 |
Novel Benzosuberone/Indanone-Linked Thiazoles as Small-Molecule SARS-CoV-2 Main Protease Inhibitors |
Thoraya A. Farghaly, Elham N. Bifari, Mariam A. Al-sheikh, Afaf Y. Khormi, Hanadi Y. Medrasi, Jihan Qurban, Hanan Gaber Abdulwahab |
| 2 |
[GO] |
2023―Mai―11 |
Identification of potential targets against SARS-CoV-2 of antiviral drugs based on photoaffinity probes |
Yuexiang Ma, Jin Wang, Xiaoyan Pan, Jie Zhang, Yuanyuan Shan |
| 3 |
[GO] |
2022―Aug―22 |
Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion |
Carlos A. Fuzo, Ronaldo B. Martins, Thais F. C. Fraga-Silva, Martin K. Amstalden, Thais Canassa De Leo, Juliano P. Souza, et al. (+9) Thais M. Lima, Lucia H. Faccioli, Débora Noma Okamoto, Maria Aparecida Juliano, Suzelei C. França, Luiz Juliano, Vania L. D. Bonato, Eurico Arruda, Marcelo Dias-Baruffi |
| 4 |
[GO] |
2022―Jun―25 |
The potential of developing a protective peptide-based vaccines against SARS-CoV-2 |
Ahmed O. Shalash, Istvan Toth, Mariusz Skwarczynski |
| 5 |
[GO] |
2022―Jun―16 |
Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs) |
Mehdi Valipour, Hamid Irannejad, Saeed Emami |
| 6 |
[GO] |
2021―Nov―11 |
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review |
Suwen Hu, Songwei Jiang, Xiang Qi, Renren Bai, Xiang-Yang Ye, Tian Xie |
| 7 |
[GO] |
2021―Jul―29 |
Emerging cases of mucormycosis under
COVID
-19 pandemic in India: Misuse of antibiotics |
Gaurav Gupta, Roshan S., Yogendra Singh, Lakshmi Thangavelu, Sachin Kumar Singh, Harish Dureja, et al. (+2) Dinesh Kumar Chellappan, Kamal Dua |
| 8 |
[GO] |
2021―Apr―13 |
Potential antiviral activity of isorhamnetin against
SARS-CoV
-2 spike pseudotyped virus in vitro |
Yingzhuan Zhan, Wenjing Ta, Wenjuan Tang, Ruochen Hua, Jue Wang, Cheng Wang, Wen Lu |
| 9 |
[GO] |
2021―Apr―03 |
TWIRLS
, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via
ACE2 |
|
| 10 |
[GO] |
2020―Nov―30 |
Review of registered clinical trials for the treatment of COVID-19 |
Fatemeh Babaei, Mohammadreza Mirzababaei, Marjan Nassiri-Asl, Hossein Hosseinzadeh |
| 11 |
[GO] |
2020―Nov―15 |
CB2
receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in
SARS-CoV
-2 infections |
M. F. Meeran, Charu Sharma, Sameer N. Goyal, Sanjay Kumar, Shreesh Ojha |
| 12 |
[GO] |
2020―Aug―08 |
Epigallocatechin gallate and theaflavin gallate interaction in
SARS-CoV
-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study |
Smarajit Maiti, Amrita Banerjee |
| 13 |
[GO] |
2020―Aug―05 |
Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers |
Irena Voinsky, David Gurwitz |
| 14 |
[GO] |
2020―Jul―31 |
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19 |
Suman Rohilla |
| 15 |
[GO] |
2020―Jul―14 |
Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus-2 proteome |
Aatika Sadia, Muhammad Asim Raza Basra |
| 16 |
[GO] |
2020―Jul―13 |
TWIRLS
, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via
ACE2 |
Xiaoyang Ji, Wenting Tan, Chunming Zhang, Yubo Zhai, Yiching Hsueh, Zhonghai Zhang, et al. (+7) Chunli Zhang, Yanqiu Lu, Bo Duan, Guangming Tan, Renhua Na, Guohong Deng, Gang Niu |
| 17 |
[GO] |
2020―Jul―07 |
Revisiting potential druggable targets against
SARS-CoV
-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review |
Abdullah Al Mamun Sohag, Md Abdul Hannan, Sadaqur Rahman, Motaher Hossain, Mahmudul Hasan, Md Kawsar Khan, et al. (+3) Amena Khatun, Raju Dash, Md Jamal Uddin |
| 18 |
[GO] |
2020―Apr―27 |
Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |
Soltan A. Ebrahimi |
| 19 |
[GO] |
2020―Apr―18 |
Response to recent commentaries regarding the involvement of a
ngiotensin-converting
enzyme 2 (
ACE2
) and
renin-angiotensin
system blockers in
SARS-CoV
-2 infections |
Robert C. Speth |
| 20 |
[GO] |
2020―Mrz―30 |
COVID-19 treatment by repurposing drugs until the vaccine is in sight |
Mrudula Phadke, Sujata Saunik |
| 21 |
[GO] |
2020―Mrz―04 |
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics |
David Gurwitz |
